Klisic, Aleksandra (56160473800)Aleksandra (56160473800)KlisicKavaric, Nebojsa (56786431000)Nebojsa (56786431000)KavaricSoldatovic, Ivan (35389846900)Ivan (35389846900)SoldatovicNinic, Ana (56607220600)Ana (56607220600)NinicKotur-Stevuljevic, Jelena (6506416348)Jelena (6506416348)Kotur-Stevuljevic2025-06-122025-06-122019https://doi.org/10.1515/labmed-2018-0325https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062660682&doi=10.1515%2flabmed-2018-0325&partnerID=40&md5=c87b62fb2054b596860213af781dd102https://remedy.med.bg.ac.rs/handle/123456789/5678Background: Retinol-binding protein 4 (RBP4) and cystatin C are regarded as novel metabolic risk markers. Therefore, we aimed to examine which one of these biomarkers better correlates with metabolic syndrome (MetS) in a cohort of postmenopausal women. Methods: A total of 129 postmenopausal women (among which 62 women had MetS) were recruited in this cross-sectional study. MetS was diagnosed according to the International Diabetes Federation criteria. Results: Cystatin C and RBP4 levels were significantly higher in women with MetS, compared to those without MetS (p=0.011 vs. p<0.001, respectively). A significant difference in the proportion of women with and without MetS across cystatin C and RBP4 quartiles was observed (χ2=5.1, p=0.025, and χ2=11.1, p=0.001, respectively). Logistic regression analysis revealed a borderline significant relationship between cystatin C and MetS (p=0.066), but this significance disappeared after adjustment for age, inflammation level and duration of menopause (p=0.221). On the contrary, a significant relationship between RBP4 and MetS was observed not only without adjustment (p=0.009), but also even after adjustment for age, inflammation level and duration of menopause (p=0.006). Conclusions: RBP4 better correlates with MetS than cystatin C in postmenopausal women. © 2019 Walter de Gruyter GmbH.cystatin Cmetabolic syndromepostmenopausalretinol-binding protein 4